Speaker illustration

Doctor Daniel Fernandez-Berges

Extremadura Health System. Don Benito-Villanueva Hospital, Villanueva de la Serena (Spain)

Member of:

European Society of Cardiology
Heart Failure Association

Daniel Fernández-Bergés MD PhD FESC Chief of the Cardiovascular Intensive Care Unit of the Institute of Cardiology of the National Academy of Medicine (1978-1991). Director of the Cardiovascular Emergencies Council and member of the Council of Specialists. (Argentine Society of Cardiology) Scientific Director of the Cardiovascular Diseases Research Program of FUNDESALUD and Head of the Research Unit of the Health area, Don Benito-Villanueva. His research has focused on cardiovascular diseases: acute coronary syndrome, atherosclerosis and its inflammatory bases, cardiovascular risk factors, clinical consequences and epidemiology. Nowadays coordinates the FREE Program (Frailty Evaluation in the Elderly) , focused on the prevalence and prognosis of frailty in patients with chronic heart failure, severe aortic stenosis pre-TAVI, severe chronic kidney failure or diabetes mellitus. Hobbies: Poetry, music, pre-Columbian cultures, traveling and walking 10 km a day

Prevalence of frailty according to different domains in chronic heart failure

Event: Heart Failure 2024

Topic: Epidemiology, Prognosis, Outcome

Session: Chronic heart failure - epidemiology, prognosis, outcome 10


Frailty prevalence among older decompensated heart failure patients

Event: ESC Congress 2023

Topic: Cardiovascular Disease in the Elderly

Session: Heart disease in the elderly: epidemiology and mechanisms


Predictors of in-hospital and late mortality in acutely decompensated chronic heart failure.

Event: ESC Congress 2019

Topic: Clinical

Session: Heart failure outcome


Mortality and atrial fibrillation in the FIACA study: evidence of a differential effect according to the diagnosis of hospital admission.

Event: ESC Congress 2017

Topic: Atrial fibrillation (AF)

Session: Comorbidities and mortalities


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb